Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions

Abstract

ObjectiveTo evaluate low-dose gadobenate dimeglumine-enhanced MRI for the differential diagnosis of malignant renal tumors.MethodsSixty-two consecutive patients with unclear diagnosis at MDCT/ultrasound underwent dynamic CE-MRI of the kidneys with 0.05 mmol/kg gadobenate dimeglumine. Retrospective image evaluation was performed by two blinded readers. Lesion diagnosis at CE-MRI was correlated with findings from histology following tumor resection or from imaging follow-up after at least 1 year. Assessments were performed of diagnostic quality and level of diagnostic information.ResultsThirty-nine (63 %) patients were correctly diagnosed with malignant lesions (36 with RCC, 2 with renal metastases, 1 with lymphoma) while 14 (22.6 %) patients were correctly diagnosed with benign (n = 12) or no (n = 2) lesions. Eight patients were considered false positive (5 with oncocytoma, 3 with atypical AML) and 1 patient false negative (atypical RCC). The sensitivity, specificity, accuracy, PPV, and NPV for the diagnosis of malignant renal lesions were 97.5 % (39/40), 63.6 % (14/22), 85.5 % (53/62), 83.0 % (39/47), and 93.3 % (14/15), respectively. Images were excellent in 60 and good in 2 patients. Minimal artifacts that did not compromise diagnosis were noted in 4/62 patients.ConclusionLow-dose gadobenate dimeglumine-enhanced MRI is effective for the differential diagnosis of malignant renal tumors.

Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas

“…This finding supports findings from Khouri Chalouhi et al, who noted significantly superior contrast enhancement with a three‐quarter (0.075 mmol/kg bw) dose of gadobenate compared to a full (0.1 mmol/kg bw) dose of gadoterate. A similar benefit for half‐dose gadobenate has been noted for a range of applications . A clear benefit of using a half dose of gadobenate for combined DSC MRI and conventional T 1 ‐weighted imaging is in patients with severe renal impairment at risk of developing NSF.…”

“…A similar benefit for half-dose gadobenate has been noted for a range of applications. [28][29][30][31] A clear benefit of using a half dose of gadobenate for combined DSC MRI and conventional T 1 -weighted imaging is in patients with severe renal impairment at risk of developing NSF. In this regard, safety authority guidelines invariably recommend the use of the lowest effective dose in such patients.…”

Clinicopathologic analysis of renal cell carcinoma containing Intratumoral fat with and without osseous metaplasia

“…While we identified a single case in which the CT was concerning for AML, the MRI findings were consistent with RCC. MRI has greater tissue sensitivity and previously has been shown to be effective for the differential diagnosis of renal masses that are inconclusive on CT or ultrasound [22]. Therefore, when a renal mass is non-diagnostic on CT, clinicians can consider further workup with to MRI help distinguish between RCC vs AML.…”

The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)

“…In demonstrating the value of half-dose gadobenate for brain tumor imaging, our study supports the findings of numerous previous studies across a range of MR imaging applications that have confirmed the diagnostic potential of gadobenate at 0.05 mmol/kg body weight. [33][34][35][36] …”